Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Recruiting now · Phase 2

Conditions studied: Autoimmune Encephalitis (AE)

In brief

This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.

Key facts

Study ID

NCT07488117

Run by

University Hospital, Toulouse

People needed

40

Starts

2026-03-31

Expected to finish

2028-01-01

Last updated by the study team

2026-05-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-80 years;
• meeting clinical criteria for "possible" AE with identified antibodies;
• newly diagnosed with symptoms <6 months;
• no second-line immunosuppressive treatment;
• high or mixed TSPO binding affinity phenotype.

You may not qualify if…

• Pregnant women;
• contraindications to MRI;
• known allergic reaction to [18F]-DPA-714; legal protection measure;
• paraneoplastic syndrome following immune checkpoint inhibitor therapy.

Where it is running

• University Hospital — Toulouse, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.